Waters and BD’s Biosciences & Diagnostic Solutions Business to Unite, Forging a New Leader in Life Sciences and Diagnostics
Framingham, MA & Franklin Lakes, NJ – July 14, 2025 – In a significant development poised to reshape the landscape of life science research and diagnostic testing, Waters Corporation and Becton, Dickinson and Company (BD) today announced a definitive agreement to combine Waters’ highly regarded Biosciences business with BD’s Diagnostic Solutions business. This strategic union will create a formidable new entity dedicated to advancing regulated, high-volume testing across a broad spectrum of critical applications.
The combination brings together two powerhouses in their respective fields, leveraging Waters’ deep expertise in chromatography, mass spectrometry, and chemistry with BD’s extensive heritage and market leadership in diagnostics, including microbiology, molecular diagnostics, and flow cytometry. The resulting enterprise is set to offer an unparalleled breadth of innovative solutions designed to meet the complex and evolving needs of laboratories, healthcare providers, and researchers worldwide.
This strategic alliance is particularly well-positioned to address the growing demand for accurate, reliable, and efficient testing in areas such as infectious disease detection, drug discovery and development, food safety, and environmental monitoring. By integrating cutting-edge technologies and a comprehensive product portfolio, the new company aims to accelerate scientific discovery, improve patient outcomes, and enhance global public health.
“We are thrilled to embark on this transformative journey with BD,” said [Name and Title of Waters Leader – if available in the source, otherwise use a generic phrase like ‘a spokesperson for Waters’]. “The synergy between our Biosciences capabilities and BD’s Diagnostic Solutions is exceptional. Together, we will unlock new opportunities to serve the critical needs of regulated and high-volume testing markets, driving innovation and delivering greater value to our customers.”
Similarly, a representative from BD expressed enthusiasm for the collaboration. “[Name and Title of BD Leader – if available in the source, otherwise use a generic phrase like ‘a spokesperson for BD’] commented, ‘This combination represents a pivotal moment for both companies. By uniting our complementary strengths, we are creating a powerful platform to advance the frontiers of science and diagnostics. Our shared commitment to quality, innovation, and customer success will be the cornerstone of this new venture.'”
The transaction, structured as a tax-free reorganization, is expected to close in the first half of fiscal year 2026, subject to customary closing conditions, including regulatory approvals and the approval of Waters’ shareholders. The combined entity will operate under a new name, which will be announced at a later date, and will be headquartered in [likely location based on the combination, though not explicitly stated if it’s a split HQ or one primary].
This strategic move is anticipated to foster significant growth and innovation, enabling the new company to better serve its global customer base and make a profound impact on scientific advancement and healthcare delivery. The union promises to deliver enhanced capabilities, expanded market reach, and a reinforced commitment to tackling some of the world’s most pressing scientific and health challenges.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing’ at 2025-07-14 10:15. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.